157 Spam-Free Article(s) Found
||Novo Nordisk A/S
Sep 03, 2015 - Bristol-Myers Squibb Company (BMY) announced that the supplemental Biologics License Application for Opdivo has been accepted with priority review by the FDA.
Sep 03, 2015 - Novartis (NVS) launched Zarxio (biosimilar version of Amgen's Neupogen) in the U.S., which became the first FDA-approved biosimilar to be launched in the country.
Sep 02, 2015 - Bristol-Myers Squibb Company (BMY) and its partner AbbVie (ABBV) announced that the BLA for Empliciti has been accepted with priority review by the FDA.
Sep 01, 2015 - Perrigo Company plc (PRGO) announced that it has acquired a leading U.S. OTC scar management brand, ScarAway, from Enaltus.
Aug 31, 2015 - Bristol-Myers Squibb Company (BMY) announced that it has entered into a research collaboration and license agreement with QIMR Berghofer Medical Research Institute.
Aug 31, 2015 - Novo Nordisk stock is a potential outperformer that is an impressive choice for growth investors, making it a security that you need to keep on your radar in the near term
Aug 27, 2015 - Novo Nordisk (NVO) announced that it intends to start the phase IIIa PIONEER program on once-daily oral semaglutide for the treatment of type II diabetes.